Aditxt, Inc. (ADTX) Short-Term Debt to Capital

High patent barriers for AditxtScore and strict FDA oversight provide protection for Aditxt (ADTX), whose success relies on the demand for preventive diagnostics and the influx of investment. The share price history with the 0.00 metric clearly demonstrates the current situation. Meanwhile, aggressive startup acquisitions have led to a critical cash shortage and a dangerous increase in debt, destabilizing the company's entire financial model.

This metric assesses the dependence of operating activities on current liabilities relative to equity, which, given the extreme liquidity risks and critical debt burden of Aditxt (ADTX), allows for the identification of the business's survival threshold. By analyzing the proportion of short-term debt to equity, an investor can distinguish strategic stabilization from systemic stagnation, determining the company's ability to withstand cash flow gaps without emergency external financing.